Abstract Body

Background: To evaluate the association between bone biomarkers and changes in bone mineral density (BMD) over 96 weeks in patients treated with atazanavir/ritonavir (ATV/r) monotherapy vs ATV/r+2 N(t)RTIs.

Methods: MODAt (NCT01511809) is a multicentric, randomized, open-label, non-inferiority trial. Patients on ATV/r 300/100mg+2 N(t)RTIs since≥48 weeks, virologically suppressed since≥24 weeks, randomized to ATV/r monotherapy (arm A) or to maintain ATV/r+2N(t)RTIs (Arm B). This sub-study included patients who maintained for 96 weeks the antiretroviral treatment assigned at randomization.
Participants underwent DXA scan and tested bone biomarkers at baseline (BL), week 48, week 96/discontinuation.
Results as median (IQR). Linear regression to evaluate the predictors of 96-week percent changes in vertebral and femoral (total proximal) BMD.

Results: 69 patients [29 patients on ATV/r monotherapy, 40 patients on ATV/r+2N(t)RTIs], age 42 (35-46) years, 84% males, 58% smokers, 17% HCV co-infected, BMI 23.6 (21.6-25.6) kg/m2, BL CD4+ 599 (432-744) cells/μL, 87% on TDF at randomization.
At lumbar spine, BL BMD was 0.975 (0.920 ; 1.047) g/cm2 and 1.016 (0.933; 1.103) g/cm2 in arm A and B, respectively (p=0.359); %change from BL to week 48 were 1.772 (-0.010; 3.998) and -0.988 (-2.270; 1.143) in arm A and B, respectively (p=0.002) while %change from BL to week 96 were 0.830 (-0.299; 2.388) and -0.811 (-3.207; 1.833) in arm A and B, respectively (p=0.075).
At total proximal femur, BL BMD was 0.929 (0.874; 0.973) g/cm2 and 0.959 (0.871; 1.024) g/cm2 in arm A and B, respectively (p=0.458); %change from BL to week 48 were 1.301 (0.020; 3.912) and -0.199 (-1.835; 1.738) in arm A and B, respectively (p=0.069) while %change from BL to week 96 were 1.321 (-0.649; 2.671) and -0.471 (-2.440; 1.209) in arm A and B, respectively (p=0.071).
BL values of bone biomarkers were similar in the two arms [Arm A: osteocalcin, 20.4 (14.2; 29.5) ng/ml; CTX-I, 0.63 (0.44; 0.82) ng/ml; vitamin D, 62 (52; 113) nmol/L; OPG, 988 (707; 1395) pg/ml; RANKL, 31 (31; 61) pg/ml; Arm B: osteocalcin, 25.2 (15.9; 33.3) ng/ml (p=0.342); CTX-I, 0.48 (0.35; 0.69) ng/ml (p=0.095); vitamin D, 99 (59; 142) nmol/L (p=0.167); OPG, 1046 (726; 1418) pg/ml (p=0.985); RANKL, 31 (31; 42)pg/ml (p=0.685)]. Results from multivariate analysis in Table 1.

Conclusions: At 96-week of ATV/r monotherapy, this strategy was associated with an increase in BMD; the benefit of ATV/r monotherapy was more evident in patients with low baseline values of RANKL.

viewer?TAG_ACTION=SECURE_FILE_DOWNLOAD&V